COMMUNIQUÉS West-GlobeNewswire

ICU Medical Announces Time of Fourth Quarter 2024 Earnings Conference Call

13/02/2025 - 22:05

SAN CLEMENTE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter [...]

Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day

13/02/2025 - 22:05

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

13/02/2025 - 22:05

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report [...]

Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

13/02/2025 - 22:15

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial [...]

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

13/02/2025 - 22:30

SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close [...]

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

13/02/2025 - 22:30

SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based [...]

Precision Optics Reports Second Quarter Fiscal Year 2025 Financial Results

13/02/2025 - 22:30

Conference Call Scheduled for today, February 13, 2025, at 5:00pm ET. GARDNER, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced [...]

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

13/02/2025 - 22:30

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF [...]

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

13/02/2025 - 22:30

Efficacy Comparable to Approved Autologous CD19 CAR Ts: Achieved Overall Response (ORR) and Complete Response (CR) Rates of 58% and 42% Across the Study and 67% and 58% with Pivotal Study Regimen, Respectively [...]

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

13/02/2025 - 22:34

WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech company, [...]

NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock

13/02/2025 - 22:34

MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock. [...]

Outset Medical Announces Resolution of Warning Letter

13/02/2025 - 22:35

SAN JOSE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

13/02/2025 - 23:00

TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

12/02/2025 - 14:03

The Company will Host a Conference Call and Webcast on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a [...]

MAPS Announces Search for New Executive Director as it Doubles Down on Advocacy and Movement Building

12/02/2025 - 14:30

MAPS’ next Executive Director will be a bold movement leader and visionary responsible for implementing MAPS' new strategic impact plan, ensuring programmatic excellence, advancing global expansion, and major donor [...]

Bluejay Therapeutics Appoints Mary Cromwell as Senior Vice President and Head of Technical Operations

12/02/2025 - 14:30

REDWOOD CITY, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics , a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver [...]

Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes

12/02/2025 - 14:50

Rebranding Invizyne Technologies, Inc to eXoZymes Inc. Changing NASDAQ ticker from IZTC to EXOZ Introducing but not trademarking “exozymes” as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE [...]

New York Blood Center Enterprises Researchers Identify New Immune Response Mechanisms in Sickle Cell Disease

12/02/2025 - 15:00

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- New York City Blood Center Enterprises (“NYBCe”) today announced that their researchers have uncovered a critical mechanism that could potentially transform treatment [...]

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

12/02/2025 - 15:00

New Patent expands patent estate covering Adial’s unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence GLEN ALLEN, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Adial [...]